Given the close correlation between TAMs and PD-L1, a clinical trial was launched to investigate the therapeutic efficacy of combination of CSF‐1R blockade (TAM-targeting therapy) with PD‐1/PD‐L1 inhibitor in several advanced solid tumors, such as lung cancer, and pancreatic cancer (42). This evidence concerns the gene PDCD1 and lung carcinoma.